Browsing by Author "Bamia, C."
Now showing items 1-3 of 3
-
Article
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
Fountzilas, George; Skarlos, Dimosthenis V.; Giannakakis, T.; Athanasiades, A.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Bamia, C.; Pavlidis, Nicholas; Kosmidis, Paraskevas A. (1994)50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
-
Article
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Athanasiades, A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Karpathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, George (1997)Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...
-
Article
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
Fountzilas, George; Athanasiades, A.; Giannakakis, T.; Briassoulis, E. Ch; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Onienaoum, A.; Kalofonos, H. P.; Pectasides, Dimitrios; Andreopoulou, E.; Bamia, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...